GCLM and breast carcinoma: In breast cancer, in the PyMT mouse cancer model, mice with decreased glutathione content due to deficiency in GCLM (glutamate cysteine ligase modifier), a subunit of glutamate cysteine ligase, necessary for glutathione synthesis or mice treated with BSO (buthionine-[S,R]-sulfoximine) to chemically inhibit glutathione synthesis, had decreased mammary tumor burden.